| Efficacy and safety of Dipyridamole in Vogt-Koyanagi-Harada Disease | Efficacy and safety of Dipyridamole in Vogt-Koyanagi-Harada Disease | ChiCTR2000030239 |
| Post-Treatment Effects of Dipyridamole On Nucleoside Transport Inhibition | Post-Treatment Effects of Dipyridamole On Nucleoside Transport Inhibition - Post-treatment dipyridamole | NL-OMON34866 |
| """Normal Coronary Artery"" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up" | """Normal Coronary Artery"" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up" | NCT00960817 |
| Dipyridamole for Immune Activation in HIV | A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987 | NCT02121756 |
| Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) | Dipyridamole Assessment for Flare Reduction in SLE | NCT01781611 |
| Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH | Comparison of Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH by the Prior Administration of a Proton-pump Inhibitor: An Open-label 2-way Randomized Cross-over Study in Healthy Male and Female Subjects Age 40-65. | NCT02251184 |
| A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety | A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety - A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole: A randomized controlled trial(JPIGANTS01) | JPRN-C000000363 |
| Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium | | NCT02782260 |
| Aspirin and dipyridamole effect on primary patency of arteriovenous grafts | Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients | TCTR20160920003 |
| EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA | EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study | NCT00562588 |
| Efficacy of Allopurinol and Dypiridamole in Acute Mania | A Double-blind, Randomized, Placebo-controlled 4-week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole in Acute Bipolar Mania. | NCT00560079 |
| Guided Imagery for headache | The effect of Guided Imagery on Severity of Dipyridamole induced headache and Physiologic parameters in patients under cardiac scan | IRCT2017052818550N2 |
| A clinical trial to study the effects of dipyridamole eye drops in the patients with symptomatic ocular surface conjunctival degenerative lesions i.e. pinguecula and pterygium. | A prospective randomized, double blind, placebo controlled pilot study to evaluate the safety and efficacy of topical dipyridamole in the treatment of symptomatic ocular surface conjunctival degenerative lesions i.e. pinguecula and pterygium. | CTRI/2018/08/015480 |
| Comparative assessment of the absorption of a generic formulation of aspirin/dipyridamole extended release capsule against the innovator aspirin/dipyridamole extended release capsule conducted under fasting conditions in healthy male and female volunteers | A single dose, randomized, blinded, bioequivalence study of a test formulation of aspirin/dipyridamole extended release capsule in a 2 way crossover comparison against the innovator aspirin/dipyridamole extended release capsule conducted under fasting conditions in healthy male and female volunteers | ACTRN12614000276651 |
| Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers | Placebo-controlled, Randomized, Double-blind Study Comparing the Effect of a Combination of 200 mg Dipyridamole With Sustained Release and 25 mg Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Volunteers and 10 Days of Treatment Alone and in Combination With Alcohol (Study no. 591002) | NCT02278302 |
| Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress | Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole | NCT00808314 |
| The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) | The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) | NCT00906035 |
| The effect of dipyridamole on the pharmacokinetics of metformin. | The effect of dipyridamole on the pharmacokinetics of metformin. - Met-Dipy interaction trial. | EUCTR2012-000363-24-NL |
| Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG? | Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG? | EUCTR2009-014299-22-NL |
| Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19) | Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19) | ChiCTR2000030055 |
| Clinical Study of Dipyridamole Tablets in the Treatment of Acute Respiratory Distress Syndrome | Clinical Study of Dipyridamole Tablets in the Treatment of Acute Respiratory Distress Syndrome | ChiCTR2300078059 |
| Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19 | A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection. | NCT05166876 |
| Study assessing the safety and anti-coronavirus response of brequinar combined with dipyridamole in patients with mild to moderate SARS-CoV-2 infection | A phase II, randomized, assessor-blind, multicenter, multi-dose, placebo-controlled study assessing the safety and anti-coronavirus response of brequinar combined with dipyridamole in patients with mild to moderate SARS-CoV-2 infection. | CTRI/2021/12/038651 |
| Clinical trial of the efficacy and safety of dipyridamole adjuvant therapy in children with IBD | Clinical trial of the efficacy and safety of dipyridamole adjuvant therapy in children with IBD | ChiCTR2100048717 |
| Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 | A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients | NCT04424901 |
| Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | NCT04391179 |
| Metformin-Dipyridamole Interaction Trial | The Effect of Dipyridamole on the Pharmacokinetics of Metformin | NCT01613755 |
| Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients | Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients | NCT06824454 |
| A DOUBLE-BLIND? PLACEBO-CONTROLLED PARALLEL ARM TRIAL TO STUDY THE EFFICACY OF A SINGLE ORAL DOSE OF THE NUCLEOSIDE TRANSPORT INHIBITOR DIPYRIDAMOLE FOR PAIN RELIEF IN PATIENTS AFTER THIRD MOLAR SURGERY - ENT1 | A DOUBLE-BLIND? PLACEBO-CONTROLLED PARALLEL ARM TRIAL TO STUDY THE EFFICACY OF A SINGLE ORAL DOSE OF THE NUCLEOSIDE TRANSPORT INHIBITOR DIPYRIDAMOLE FOR PAIN RELIEF IN PATIENTS AFTER THIRD MOLAR SURGERY - ENT1 | EUCTR2007-000901-31-BE |
| Does short dipyridamole administration induce protection against ischemia-reperfusion injury? | Does short dipyridamole administration induce protection against ischemia-reperfusion injury? - dipy003 | NL-OMON31190 |
| Combined aspirin, clopidogrel and dipyridamole versus aspirin alone in stroke secondary prevention: a safety, tolerability and feasibility study | | ISRCTN83673558 |
| The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi | The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi | ACTRN12605000153617 |
| Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients | A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. | NCT00129038 |
| Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer | INTRAPERITONEAL METHOTREXATE AND DIPYRIDAMOLE AS SALVAGE TREATMENT FOR ADVANCED OVARIAN CARCINOMA | NCT00002487 |
| S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma | NCT00003018 |
| Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects | Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) 200/25 mg Capsules Bid and in a Combination of Persantin Immediate Release Tablets (100 mg Qid) and ASA Tablets (25 mg Bid) in an Open, Randomized, 2-way Crossover Study in Healthy Subjects | NCT02273505 |
| The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia | The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia. | NCT01091571 |
| Comparison between Dipyridamole and Adenosine infusion in the evaluation of intermediate coronary restrictions (stenoses) in the cardiac catheterization laboratorY. | Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY - DAISY | EUCTR2010-024485-21-IT |
| Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake | Ticagrelor and Adenosine Uptake. Phase II Study Comparing the Effects of Ticagrelor vs Dipyridamole on Adenosine Uptake | NCT01690884 |
| Prospective, randomized, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of stroke onset on an acute stroke unit, and Aggrenox® b.i.d. when started after a 7-day therapy with ASA 100 mg once daily outside off an acute stroke unit, in symptomatic ischaemic stroke patients over a three months treatment period (EARLY) – An exploratory studyGerman title:Prospektive, randomisierte, nationale, offene Multicenterstudie mit verblindeter Endpunktanalyse zum Vergleich von Aggrenox® Retardkapseln (200 mg Dipyridamol + 25 mg Acetylsalicylsäure) 2x täglich, Behandlungsbeginn innerhalb von 24 Stunden nach einem ischämischem Schlaganfall auf einer Stroke unit, versus Aggrenox® Retardkapseln b.i.d., Behandlungsbeginn außerhalb einer Stroke unit nach einer 7-tägigen Therapie mit 100 mg Acetylsalicylsäure pro Tag bei symptomatischen Patienten für einen Behandlungszeitraum von drei Monaten (EARLY) – Phase IV Studie - EARLY | Prospective, randomized, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of stroke onset on an acute stroke unit, and Aggrenox® b.i.d. when started after a 7-day therapy with ASA 100 mg once daily outside off an acute stroke unit, in symptomatic ischaemic stroke patients over a three months treatment period (EARLY) – An exploratory studyGerman title:Prospektive, randomisierte, nationale, offene Multicenterstudie mit verblindeter Endpunktanalyse zum Vergleich von Aggrenox® Retardkapseln (200 mg Dipyridamol + 25 mg Acetylsalicylsäure) 2x täglich, Behandlungsbeginn innerhalb von 24 Stunden nach einem ischämischem Schlaganfall auf einer Stroke unit, versus Aggrenox® Retardkapseln b.i.d., Behandlungsbeginn außerhalb einer Stroke unit nach einer 7-tägigen Therapie mit 100 mg Acetylsalicylsäure pro Tag bei symptomatischen Patienten für einen Behandlungszeitraum von drei Monaten (EARLY) – Phase IV Studie - EARLY | EUCTR2006-004870-28-DE |
| Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler | Phase 2, Monocentric, Single Blind Study, Comparing the Efficacy and Tolerance of a Dipyridamole/Adenosine Combination Given Intravenously, as a Slow Bolus and at Low Doses to Adenosine Alone for Coronary Flow Reserve Assessment (in Patients With Stable Ischemic Heart Disease) Using Transthoracic Echodoppler | NCT01593644 |
| The effects of oral dipyridamole treatment on the innate immune response during human endotoxemia. | The effects of oral dipyridamole treatment on the innate immune response during human endotoxemia. - Effects of dipyridamole on innate immune response during human endotoxemia. | NL-OMON34679 |
| Etude clinique de phase II, monocentrique, en simple aveugle comparant l'efficacité et la tolérance de l'administration intraveineuse de dipyridamole et d'adénosine donnés séquentiellement ou de façon concomitante à faible doses, à l'adénosine seule donnée à la dose standard usuelle, dans l'évaluation de l'ischémie myocardique par scintigraphie au technetium sestamibi. - non applicable | Etude clinique de phase II, monocentrique, en simple aveugle comparant l'efficacité et la tolérance de l'administration intraveineuse de dipyridamole et d'adénosine donnés séquentiellement ou de façon concomitante à faible doses, à l'adénosine seule donnée à la dose standard usuelle, dans l'évaluation de l'ischémie myocardique par scintigraphie au technetium sestamibi. - non applicable | EUCTR2006-005750-68-FR |
| Comparative assessment of the absorption of a generic formulation of aspirin/dipyridamole extended release capsule against the innovator aspirin/dipyridamole extended release capsule conducted under fed conditions in healthy male and female volunteers | A single dose, randomized, blinded, bioequivalence study of a test formulation of aspirin/dipyridamole extended release capsule in a 2 way crossover comparison against the innovator aspirin/dipyridamole extended release capsule conducted under fed conditions in healthy male and female volunteers | ACTRN12614000275662 |
| Is intensive blood thinning with three antiplatelet drugs better than the current guideline treatment in reducing recurrence after acute stroke? | Safety and efficacy of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke or TIA: a randomised controlled trial - TARDIS | EUCTR2007-006749-42-GB |
| Dipyridamole/Magnesium To Improve Sickle Cell Hydration | Dipyridamole/Magnesium To Improve Sickle Cell Hydration | NCT00276146 |
| Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole | Enhancement of Postocclusive Reactive Hyperaemia | NCT00268554 |
| Dipyridamol opbouw in secundaire preventie van beroerte. | A prospective randomised open label study to determine the best dose escalation schema of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke. | NL-OMON24084 |
| Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? | Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? | NCT00457405 |
| Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? | Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? | NCT00430170 |
| A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. | A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. - A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. | JPRN-C000000374 |
| Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow Phenomenon | Placebo controlled, randomised, crossover study of the efficacy of dipyridamole in reducing the number of angina episodes in patients with Coronary Slow Flow Phenomenon (CSFP) | ACTRN12606000236594 |
| Clinical Trial of Dipyridamole in Schizophrenia | Clinical Trial of Dipyridamole in Schizophrenia | NCT00349973 |
| A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. | A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. - A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. | JPRN-C000000375 |
| Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury? | Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury? - dipy001 | NL-OMON30237 |
